Online Purchasing Account You are logged on as Guest. LoginRegister a New AccountShopping cart (Empty)
United States 


PARP inhibitor
BML-AP101-0020 20 mg 110.00 USD
BML-AP101-0100 100 mg 431.00 USD
Do you need bulk/larger quantities?
Replaces Prod. #: ALX-270-250

Potent inhibitor of poly (ADP-ribose) polymerase-1 (PARP-1) (IC50=0.18μM). Reduces ischemia-reperfusion injury in the heart and skeletal muscle.

Product Details

Alternative Name:4-ANI
Purity:≥96% (NMR)
Appearance:Orange solid.
Solubility:Soluble in DMSO (5mg/ml).
Shipping:Ambient Temperature
Long Term Storage:Ambient
Use/Stability:Stable for at least 1 year after receipt when stored, as supplied, at room temperature. Stock solutions are stable for up to 3 months at -20°C.
Regulatory Status:RUO - Research Use Only
Please mouse over

Product Literature References

Disrupted ADP-ribose metabolism with nuclear Poly (ADP-ribose) accumulation leads to different cell death pathways in presence of hydrogen peroxide in procyclic Trypanosoma brucei: M. Schlesinger, et al.; Parasit. Vectors 9, 173 (2016), Application(s): Potency of inhibitors, Abstract; Full Text
The role of NF-κB in PARP-inhibitor-mediated sensitization and detoxification of arsenic trioxide in hepatocellular carcinoma cells: Q. Luo, et al.; J. Toxicol. Sci. 40, 349 (2015), Application(s): Cell Culture, Abstract; Full Text
Targeting of NAD metabolism in pancreatic cancer cells: potential novel therapy for pancreatic tumors: C.C. Chini, et al.; Clin. Cancer Res. 20, 120 (2014), Abstract;
4-Amino-1,8-naphthalimide: a novel inhibitor of poly(ADP-ribose) polymerase and radiation sensitizer: A. Schlicker, et al.; Int. J. Radiat. Biol. 75, 91 (1999), Abstract;
Effects of inhibitors of the activity of poly (ADP-ribose) synthetase on the liver injury caused by ischaemia-reperfusion: a comparison with radical scavengers: J. Bowes & C. Thiemermann; Br. J. Pharmacol. 124, 1254 (1998), Abstract;
Inhibition of the activity of poly(ADP ribose) synthetase reduces ischemia-reperfusion injury in the heart and skeletal muscle: C. Thiemermann, et al.; Proc. Natl. Acad. Sci. USA 94, 679 (1997), Abstract;
Combination effects of poly(ADP-ribose) polymerase inhibitors and DNA-damaging agents in ovarian tumor cell lines--with special reference to cisplatin: F. Bernges, et al.; J. Cancer Res. Clin. Oncol. 122, 665 (1996), Abstract;
Nitric oxide toxicity in islet cells involves poly(ADP-ribose) polymerase activation and concomitant NAD+ depletion: J. Radons, et al.; Biochem. Biophys. Res. Commun. 199, 1270 (1994), Abstract;
Specific inhibitors of poly(ADP-ribose) synthetase and mono(ADP-ribosyl)transferase: M. Banasik, et al.; J. Biol. Chem. 267, 1569 (1992), Abstract;

Product Toolbox


Certificate of Analysis


By target:
By biological activity:
PARP Inhibitor
By catalog section:


Technical Service
Customer Service

Related Literature

Product Flyers
The PARP Family & ADP Ribosylation
The PARP Family & ADP Ribosylation
Download as PDF

All new literature pieces